Targovax to present at upcoming conferences

Oslo, 11 May 2022 – Targovax ASA announces that members of its executive management team and key scientist are invited to present at upcoming conferences:

33rd Annual Cancer Progress Conference, virtual
Panel:  Victor Levitsky (CSO)
Panel title: Cancer Vaccines Redux: mRNA, Oncolytic Viruses, Or Good Old-Fashioned Peptides – Is It the Target(s), Immunization Platform, Clin Dev Strategy, or All of the Above?
Date: 11 May 2022
Time: 13:30 CET

Preclinical Immuno-Oncology, virtual
Presentation: Thomas B Hansen (VP Research)
Date: 18 May 2022
Time: 12:25 BST /13:25 CET

ABGSC Life Science Summit 2022, virtual
Presentation:  Erik Digman Wiklund (CEO)
Date: 19 May 2022
Time: 10:30 CET

8th Annual Immuno-Oncology Innovation Forum, virtual
Panel: Lubor Gaal (CFO)
Panel title: Optimizing the Inherent Combination Value of Oncolytic Viruses Panel
Date: 25 May 2022
Time: 14:20 EDT / 20:20 CET

The presentations will be available on www.targovax.com after the conferences.

***

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax’s focus is to activate the patient’s immune system to fight cancer, and thereby bring benefit to cancer patients with few available treatment alternatives. Targovax is assessing its product candidates in different cancer indications, including melanoma, mesothelioma, and colorectal cancer, and has demonstrated a favorable safety and tolerability profile.

Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer. On the back of very encouraging clinical data in several indications, both as monotherapy and in immunotherapy and chemotherapy combinations, the next development step for ONCOS-102 will be to further improve immune activation and clinical response in melanoma patients resistant to PD1 checkpoint blockade.

Building on successful phase 1/2 studies demonstrating clinical benefit and providing deep mechanistic insights, Targovax is expanding its ONCOS program into delivery of circular RNA and targeting KRAS mutant cancers with the aim of establishing a platform for development of a rich pipeline of innovative future immunotherapy product candidates.